The new version of Sarclisa stems from a collaboration with Enable Injections, backed financially to the tune of €300 million ...

Paris: Sanofi has received orphan drug designation from the US Food and Drug Administration (FDA) for rilzabrutinib, a novel, ...

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics, Inc. (NASDAQ:NRIX) with a price target ...

Marc Frahm, an analyst at TD Cowen, downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) from Buy to Hold. This ...

Morgan Stanley analyst Sarita Kapila resumed coverage of Sanofi (NASDAQ:SNY), assigning an Equal Weight rating and setting a $56 price target.

A French pharmaceutical giant is acquiring a biotech and its rare immunology disease treatment which is already approved in ...

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...